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Available online 22 October 2015During the 4th Asia Paciﬁc Prostate Cancer Conference, dele-
gates who primarily consisted of medical oncologists, urologists,
and radiologists were asked to participate in a pre-meeting survey
to discover how prostate cancer is managed in the Asia Paciﬁc re-
gion. One hundred and eighteen of the 172 delegates responded to
the survey and they were from 12 different countries (Australia,
China, Hong Kong, India, Indonesia, Japan, Korea, Malaysia,
Singapore, Taiwan, Thailand, and Vietnam). About 80% of the re-
sponders were from the public sector. The survey results revealedFig. 1. Patient's PSA response to treatment courses. LHRH, luteinizing hormone-releasing
withdrawal syndrome; ENZ, enzalutamide.
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p2287-8882 e2287-903Xthat the rise in the ageing population was one of the main factors
(as indicated by 97% of respondents) for the increase in the inci-
dence of prostate cancer in the Asia Paciﬁc region. This case study
presentation explored the use of full dose abiraterone in an elderly
Asian patient with castration-resistant prostate cancer (CRPC).
An 87-year-old male whose chief complaint was frequent uri-
nation, was diagnosed with stage T3bN1M0 prostate cancer. Initial
prostate-speciﬁc antigen (PSA) was 86.75 ng/ml, and Gleason score
was 4þ5. The patients' PSA responses to treatments are shown in
Fig. 1.
During treatment with enzalutamide, this patient experienced
fatigue, appetite loss, and constipation. With abiraterone, the pa-
tient did not report any adverse events. By the end of the treatment
period, CT, MRI, and RI examinations revealed no new lesions, and
the patient had no other disease symptoms.
Once patients are prescribed novel agents for the treatment of
prostate cancer, there are currently no ﬁxed criteria to determinehormone; CAB, combined androgen blockade; BCL, bicalutamide; AWS, antiandrogen
Fig. 2. Audience's opinions on subsequent treatments following cessation of abir-
aterone for this patient case.
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have good response with abiraterone, the audience at the meeting
was asked for their opinions as to how long this patient should be
kept on abiraterone. In total, 78% of the audience present at the 4th
Asia Paciﬁc Prostate Cancer Conference indicated that this patient
should be kept on abiraterone until radiographical or clinical pro-
gression. The St Gallen Advanced Prostate Cancer Consensus Con-
ference Expert Panel recommended that treatment should only be
ceased when at least two of three criteria (PSA progression,
radiographic progression and clinical deterioration) were fulﬁlled.1
Further to this, the audience was also asked which subsequent
treatment this patient should receive, upon cessation ofabiraterone. About one-in-three recommended ‘best supportive
care’ and about one-in-four recommended ‘other drugs’. 18% of the
audience voted to re-challenge with enzalutamide (Fig. 2).
Further, local experience with abiraterone in a limited number
of elderly (>80 years old) patients with mCRPC was also presented.
Based on experience, full dose abiraterone appears to be feasible
and well tolerated, even in elderly patients with mCRPC. In patients
who are responding well to treatments with novel agents, there is
currently no recommendation from practice guidelines regarding
when to cease treatment.Conﬂict of interest
SO received research support/acted as a Principal Investigator in
studies sponsored Astellas, Astra Zeneca, Takeda, Nippon Kayaku
and Sanoﬁ.
SO has been a speaker at meetings sponsored by Astellas, Astra
Zeneca, Janssen, Sanoﬁ, Takeda.
SO sits on a scientiﬁc advisory board for Astellas.References
1. Gillessen S, Omlin A, Attard G, de Bono JS, Efstathiou E, Fizazi K, Halabi S, et al.
Management of patients with advanced prostate cancer: recommendations of
the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015.
Ann Oncol. 2015;26:1589e604.
